Bayer AG is moving into the development of protein degraders through a deal with Arvinas Inc. worth $50m upfront.
The potential for bifunctional small molecules to use cellular machinery to eliminate disease-causing proteins has attracted considerable interest, in large part because it offers a potential way to drug the estimated 80% of proteins that are beyond the reach of existing small molecules
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?